Our Magazine
Brussels Morning Online Newspaper
Tuesday, April 20, 2021
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Online Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Online Newspaper
No Result
View All Result
Home Europe

France’s Servier pharmaceuticals on trial for hundreds of deaths

Nikola Kiš by Nikola Kiš
29 March 2021
in Europe
France’s Servier pharmaceuticals on trial for hundreds of deaths
Share on FacebookShare on Twitter

Brussels (Brussels Morning) The French Servier pharmaceuticals company is on trial for hundreds of deaths blamed on its weight loss pill Mediator, France24 reported on Monday.

Mediator was on the market for 33 years before being withdrawn in 2009, a decade more or less after concerns were first raised about the drug causing serious heart problems. Some five million people used the drug.

More than 6,500 plaintiffs, including health insurance funds, are seeking damages of one billion euro from manufacturer Servier.

Company faces multiple charges 

The company is accused of causing unintentional injury, manslaughter, fraud and aggravated deceit. Investigators maintain that Servier knowingly concealed the risks that the drug posed for years. The company rejects the accusations.

Twelve people and 11 legal entities, including Servier, nine of its subsidiaries and the National Agency for Medicines and Health Products Safety (ANSM), were tried in 2019 and 2020 for their roles in the scandal which undermined trust in the French pharmaceutical industry.

Jean-Philippe Seta, the former deputy chief executive officer at Servier, previously conceded that the company had “made mistakes”. He faces jail time if convicted.

While Mediator was initially intended for treating overweight people with diabetes, the drug was regularly prescribed to healthy people as a weight loss drug.

One witness testifying against Servier pointed out that she had lost ten kilograms in the first month of using the drug and that she continued to take Mediator for three years before being diagnosed with heart disease.

Caused 500-to-2,100 deaths

The estimated death toll ranges from between 500 and 2,100. To date, thousands of consumers have already settled with the company to the tune of some 200 million euro in total.

Servier claims it was unaware of the risk the drug posed until 2009, when it was withdrawn from the market in France. By then, the drug had been outlawed in Italy, Spain and the US.

The ANSM has accepted its “share of responsibility” for the delayed banning of the drug.

Subscribe to Our Newsletter

Tags: Main-Slider
Nikola Kiš

Nikola Kiš

Nikola is Brussels Morning political affairs reporter, covering Germany, France, and Italy. Based in Zagreb, he is a translator with 18 years of experience reporting on political and business affairs.

Latest post

Iran names fugitive citizen suspected of Natanz attack

Iran names fugitive citizen suspected of Natanz attack

1 hour ago
EU expands sanctions against Myanmar junta

EU expands sanctions against Myanmar junta

2 hours ago

Most Read

  • A very Georgian provokatsiya

    A very Georgian provokatsiya

    0 shares
    Share 0 Tweet 0
  • EC to investigate €1bn worth of missing lumber in Croatian forests

    0 shares
    Share 0 Tweet 0
  • Salmond’s strategic masterstroke

    0 shares
    Share 0 Tweet 0
  • The explorer of non-places: interview with one of the world’s most intrepid travellers

    0 shares
    Share 0 Tweet 0
  • Seeking climate consensus amidst Sino-American rivalry

    0 shares
    Share 0 Tweet 0

Subscribe
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • EU Institutions
    • Parliament
    • Commission
    • Council
  • Europe
  • World
  • Member States
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • The American Angle
    • Southeast Europe
  • Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT